scispace - formally typeset
A

Alicia Garrido

Researcher at University of Barcelona

Publications -  29
Citations -  1092

Alicia Garrido is an academic researcher from University of Barcelona. The author has contributed to research in topics: Parkinsonism & Parkinson's disease. The author has an hindex of 9, co-authored 26 publications receiving 390 citations. Previous affiliations of Alicia Garrido include University College London.

Papers
More filters
Journal ArticleDOI

Challenges in the diagnosis of Parkinson's disease

TL;DR: Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development.
Journal ArticleDOI

Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study

TL;DR: Investigation of whether neuroinflammation is present in patients with IRBD and its possible relation to nigrostriatal dopamine function found increased microglial activation was detected by PET in the substantia nigra along with reduced dopaminergic function in the putamen.
Journal ArticleDOI

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Götz Thomalla, +775 more
- 14 Nov 2020 - 
TL;DR: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care despite an increased risk of symptomatic intracranial haemorrhage.
Journal ArticleDOI

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

Tanya Simuni, +132 more
- 01 Jan 2020 - 
TL;DR: The authors' data show evidence of subtle motor and non-motor signs of Parkinson's disease in non-manifesting carriers compared with healthy controls that can precede DAT deficit.